Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 12-Month Low - Should You Sell?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report)'s stock price hit a new 52-week low on Monday . The company traded as low as $16.26 and last traded at $16.43, with a volume of 68011 shares. The stock had previously closed at $16.97.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a "sell" rating in a research note on Friday, December 20th. Citigroup lowered their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Wednesday, November 27th. Piper Sandler dropped their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an "overweight" rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein lowered their target price on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a "market perform" rating on the stock in a report on Friday, November 29th. Finally, B. Riley reissued a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $41.44.

Remove Ads

Arrowhead Pharmaceuticals Trading Down 4.4 %

The stock has a market cap of $1.90 billion, a P/E ratio of -2.91 and a beta of 0.92. The business's 50 day simple moving average is $19.18 and its 200 day simple moving average is $20.32. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, Director Adeoye Y. Olukotun sold 2,850 shares of the stock in a transaction that occurred on Friday, December 27th. The shares were sold at an average price of $20.00, for a total transaction of $57,000.00. Following the sale, the director now directly owns 36,740 shares of the company's stock, valued at $734,800. This represents a 7.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Christopher Richard Anzalone sold 133,333 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the completion of the transaction, the chief executive officer now owns 3,773,802 shares of the company's stock, valued at $64,230,110.04. This trade represents a 3.41 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 280,765 shares of company stock valued at $5,227,313. Corporate insiders own 4.30% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. R Squared Ltd bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at about $38,000. GF Fund Management CO. LTD. bought a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $49,000. Van ECK Associates Corp raised its stake in shares of Arrowhead Pharmaceuticals by 72.3% during the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock worth $56,000 after buying an additional 1,250 shares during the last quarter. KBC Group NV boosted its stake in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after acquiring an additional 1,644 shares during the last quarter. Finally, Mackenzie Financial Corp bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at $137,000. 62.61% of the stock is currently owned by institutional investors.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.